{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T03:53:22Z","timestamp":1791604402695,"version":"4.3.4"},"reference-count":39,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["eJHaem"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Patients with multiple myeloma (MM) and chronic lymphocytic leukaemia (CLL) are burdened by immunodeficiency due to treatment and underlying disease. Infection\u2010related mortality remains a significant concern for patients' overall survival (OS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This Swedish, population\u2010based study examined incidence of infections and OS in patients with MM or CLL between January 2010 and December 2021, using Swedish Cancer Registry data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Overall, 15,766 patients were included (MM: 8532; CLL: 7234); the majority were male (MM: 57%; CLL: 62%); median age was 71 years (range: 19\u2013100 [MM]; 23\u2013102 [CLL]). The proportion with a Charlson Comorbidity Index \u2265 5 was 37% (MM) and 25% (CLL). At least one infection was reported in 66% (MM;\n                      <jats:italic>n<\/jats:italic>\n                      = 5618) and 50% (CLL;\n                      <jats:italic>n<\/jats:italic>\n                      = 3618), with a median follow\u2010up of 3.3 and 4.8 years, respectively. Pneumonia was the most common bacterial infection (21% for both), while herpes zoster was the most common specified viral infection (MM: 2.6%; CLL: 3.5%). Median OS (95% confidence interval) among these patients was 4.7 (4.6\u20134.9) and 9.7 (9.3\u201310.2) years, respectively. Infection (any) was the underlying\/contributing cause of death for 1251\/4822 (26%) deceased patients (MM) and 835\/2571 (33%) (CLL). Higher comorbidity, prior infection and prophylaxis were associated with increased infection risk, while age, female sex and more recent diagnosis were associated with reduced risk.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study demonstrates high mortality rates among patients with MM and CLL, due to underlying malignancy and high infection burden. This emphasises the need for optimised anticancer treatments and infection control strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>The authors have confirmed clinical trial registration is not needed for this submission.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/jha2.70363","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T14:44:53Z","timestamp":1785509093000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Infection Incidence and Survival in Patients With Multiple Myeloma and Chronic Lymphocytic Leukaemia: A Growing Concern in the Era of Modern Therapies"],"prefix":"10.1002","volume":"7","author":[{"given":"Ingrid","family":"Glimelius","sequence":"first","affiliation":[{"name":"Department of Immunology, Genetics and Pathology, Cancer Precision Medicine Uppsala University  Uppsala Sweden"},{"name":"Blood Oncology and Tumour Disease Oncology Clinic Akademiska University Hospital  Uppsala Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Love","family":"T\u00e4tting","sequence":"additional","affiliation":[{"name":"Department of Haematology in Link\u00f6ping and Department of Biomedical and Clinical Sciences Link\u00f6ping University  Link\u00f6ping Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonatan","family":"Freilich","sequence":"additional","affiliation":[{"name":"Access Consulting \u2013 RWE Parexel International  Stockholm Sweden"},{"name":"Department of Public Health and Clinical Medicine Ume\u00e5 University  Ume\u00e5 Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Natalia Stelmaszuk","sequence":"additional","affiliation":[{"name":"Access Consulting \u2013 RWE Parexel International  Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Yang","sequence":"additional","affiliation":[{"name":"RWE Consulting \u2013 Epidemiology &amp; COA Parexel International  Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Deleskog","sequence":"additional","affiliation":[{"name":"Takeda Pharma AB  Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigur\u00f0ur Y.","family":"Kristinsson","sequence":"additional","affiliation":[{"name":"Faculty of Medicine University of Iceland  Reykjavik Iceland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,7,31]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.738915"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.107714"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/bmb\/ldn034"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.7150\/jca.29993"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13102468"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/cnr2.70027"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352\u20103026(22)00165\u2010X"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.840616"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25681"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1062376"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00033"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12196356"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2019.04.029"},{"key":"e_1_2_12_15_1","unstructured":"National Board of Health and Welfare for Sweden \"National Patient Register \"2024 https:\/\/www.socialstyrelsen.se\/en\/statistics\u2010and\u2010data\/registers\/national\u2010patient\u2010register\/."},{"key":"e_1_2_12_16_1","unstructured":"National Board of Health and Welfare for Sweden \"National Prescribed Drug Register \"2024 https:\/\/www.socialstyrelsen.se\/en\/statistics\u2010and\u2010data\/registers\/national\u2010prescribed\u2010drug\u2010register\/."},{"key":"e_1_2_12_17_1","unstructured":"National Board of Health and Welfare for Sweden \"National Cancer Register \"2024 https:\/\/www.socialstyrelsen.se\/en\/statistics\u2010and\u2010data\/registers\/national\u2010cancer\u2010register\/."},{"key":"e_1_2_12_18_1","unstructured":"National Board of Health and Welfare for Sweden \"National Cause of Death Register \"2024 https:\/\/www.socialstyrelsen.se\/en\/statistics\u2010and\u2010data\/registers\/national\u2010cause\u2010of\u2010death\u2013register\/."},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10654\u2010025\u201001226\u20109"},{"key":"e_1_2_12_20_1","unstructured":"Socialstyrelsen: The National Board of Health and Welfare \"Statistics on Multiple Causes of Death 2023 https:\/\/www.socialstyrelsen.se\/contentassets\/4dd918e6ad2b42608bad45c9675f2ed4\/2023\u20105\u20108523.pdf."},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13133240"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.11.014"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13205154"},{"key":"e_1_2_12_24_1","unstructured":"Regionernas Samverkansmodell F\u00f6r L\u00e4kemedel \"Darzalex (Daratumumab) Vid Multipelt Myelom \"2024 https:\/\/samverkanlakemedel.se\/download\/18.25cdd0fd18e65a1a5d02e1d2\/1650529785060\/Darzalex\u2010(daratumumab)\u2010220421.pdf."},{"key":"e_1_2_12_25_1","unstructured":"Onkologi \"The NT Council Recommends the Use of Darzalex as Combination Therapy in Multiple Myeloma \"2024 https:\/\/www\u2010onkologiisverige\u2010se.translate.goog\/nt\u2010radet\u2010rekommenderar\u2010anvandning\u2010av\u2010darzalex\u2010som\u2010kombinationsbehandling\u2010vid\u2010multipelt\u2010myelom\/?_x_tr_sl=sv&_x_tr_tl=en&_x_tr_hl=en&_x_tr_pto=sc."},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2024.10.3243"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac574"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.09.019"},{"key":"e_1_2_12_29_1","unstructured":"Regional Cancer Centres in Collaboration \"National Quality Registry Chronic Lymphocytic Leukemia \"2025 https:\/\/cancercentrum.se\/diagnosbehandling\/cancerdiagnoser\/hematologiskacancersjukdomar\/kronisklymfatiskleukemikll\/kvalitetsregister.7188.html."},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17010119"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277\u2010024\u201005625\u2010y"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277\u2010024\u201006101\u20103"},{"issue":"1","key":"e_1_2_12_33_1","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3324\/haematol.2024.285645","article-title":"Risk of Infections in Multiple Myeloma. A Population\u2010Based Study on 8672 Multiple Myeloma Patients Diagnosed 2008\u20132021 From the Swedish Myeloma Registry","volume":"110","author":"Blimark C. H.","year":"2025","journal-title":"Haematologica"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13553"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.121"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41416\u2010024\u201002816\u20102"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.105"},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70613"},{"key":"e_1_2_12_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40121\u2010020\u201000313\u20106"},{"key":"e_1_2_12_40_1","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S413587"}],"container-title":["eJHaem"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jha2.70363","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jha2.70363","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jha2.70363","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T03:43:06Z","timestamp":1791603786000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jha2.70363"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,31]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1002\/jha2.70363"],"URL":"https:\/\/doi.org\/10.1002\/jha2.70363","archive":["Portico"],"relation":{},"ISSN":["2688-6146","2688-6146"],"issn-type":[{"value":"2688-6146","type":"print"},{"value":"2688-6146","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,31]]},"assertion":[{"value":"2026-02-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-31","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70363"}}